< Back to previous page
Project
BetaSCREEN: platform for drug screening in diabetes (IWT556)
BETA-CELL is a privately owned biopharmaceutical company that develops novel cell therapy and other products related to Diabetes.
The company is a spin-off from the Brussels Free University - Diabetes Research Center (VUB-DRC), established in 1998. The DRC is a leader in the biology of insulin-producing beta cells and its use as platform for novel methods in the diagnosis and treatment of diabetes. It has particular expertise in cell isolation and quality control, stem/precursor cell characterization and differentiation, preparation of standardized beta cell grafts and organization and funding of multi-center clinical trials in diabetes patients.
DRC is an internationally recognized center of excellence in the field of diabetes. BETA-CELL's technology platform is based on prior, current and future work at the DRC. It has acquired proprietary technology for a first product line, with BetaGRAFT as a lead, and has an agreement on its first right of refusal on all diabetes related Intellectual Property (IP) generated at DRC.
Recent developments have opened a second line in the field of beta cell regeneration, with BetaREG as a lead, and a third one in the field of drug screening and discovery, defined as BetaSCREEN
The company is a spin-off from the Brussels Free University - Diabetes Research Center (VUB-DRC), established in 1998. The DRC is a leader in the biology of insulin-producing beta cells and its use as platform for novel methods in the diagnosis and treatment of diabetes. It has particular expertise in cell isolation and quality control, stem/precursor cell characterization and differentiation, preparation of standardized beta cell grafts and organization and funding of multi-center clinical trials in diabetes patients.
DRC is an internationally recognized center of excellence in the field of diabetes. BETA-CELL's technology platform is based on prior, current and future work at the DRC. It has acquired proprietary technology for a first product line, with BetaGRAFT as a lead, and has an agreement on its first right of refusal on all diabetes related Intellectual Property (IP) generated at DRC.
Recent developments have opened a second line in the field of beta cell regeneration, with BetaREG as a lead, and a third one in the field of drug screening and discovery, defined as BetaSCREEN
Date:1 Apr 2013 → 31 Mar 2014
Keywords:Cell Therapy, Prevention, Transplantation, Diagnostic Tests, Immunology, Cell Death and Survival, Islet Cell Pathology, Islet Cell Biology, Beta Cell Transplantation, Diabetes
Disciplines:Basic sciences, Biological sciences